Literature DB >> 9752821

Tolcapone and fulminant hepatitis.

F Assal, L Spahr, A Hadengue, L Rubbia-Brandt, P R Burkhard, L Rubbici-Brandt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9752821     DOI: 10.1016/s0140-6736(05)61511-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

1.  Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

Authors:  L Spahr; L Rubbia-Brandt; P R Burkhard; F Assal; A Hadengue
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

Review 2.  Comparative tolerability of the newer generation antiparkinsonian agents.

Authors:  D Lambert; C H Waters
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 3.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

4.  Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

Authors:  Saviana Di Giovanni; Simona Eleuteri; Katerina E Paleologou; Guowei Yin; Markus Zweckstetter; Pierre-Alain Carrupt; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

Review 5.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

6.  Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.

Authors:  A J Lees; V Ratziu; E Tolosa; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

Review 7.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

8.  Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning.

Authors:  Yeong-Liang Lin; Ya-Chi Wu; Churn-Shiouh Gau; Min-Shung Lin
Journal:  Ther Adv Drug Saf       Date:  2012-02

Review 9.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

10.  Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.

Authors:  Ronald G Robinson; Sean M Smith; Scott E Wolkenberg; Monika Kandebo; Lihang Yao; Christopher R Gibson; Scott T Harrison; Stacey Polsky-Fisher; James C Barrow; Peter J Manley; James J Mulhearn; Kausik K Nanda; Jeffrey W Schubert; B Wesley Trotter; Zhijian Zhao; John M Sanders; Robert F Smith; Debra McLoughlin; Sujata Sharma; Dawn L Hall; Tiffany L Walker; Jennifer L Kershner; Neetesh Bhandari; Pete H Hutson; Nancy A Sachs
Journal:  ACS Chem Neurosci       Date:  2011-11-14       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.